12:00 AM
 | 
Jul 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Northera droxidopa: Additional Phase III data

Pooled data from 263 patients from the double-blind Phase III Study 301 and 302 trials showed that Northera significantly improved mean OHQ composite score vs. placebo (p=0.001). The 11-point OHQ measures the severity of 6 symptoms on the OHSA scale and 4 patient function criteria on the OHDAS scale. On the OHSA, Northera significantly reduced mean dizziness (p=0.004), weakness (p=0.004) and fatigue (p=0.013) scores vs. placebo, but non-significantly improved vision, head/neck discomfort and concentration scores. On the OHDAS, Northera significantly reduced mean standing short time (p=0.001), standing long...

Read the full 419 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >